Dr. Shain Discusses the Role of Stem Cell Transplant in Myeloma

Kenneth H. Shain, MD, PhD
Published: Wednesday, Sep 12, 2018



Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

If chimeric antigen receptor (CAR) T-cell therapy is taken out of the mix, stem cell transplant remains a critical part of the management of newly diagnosed patients, Shain says. The data continue to evolve in terms of overall survival benefit. However, progression-free survival and depth of response is where the inclusion of transplant has its greatest impact. The ideal sequence of treatment for this patient population is induction therapy, transplant, and then maintenance therapy, Shain says. Without transplant, the outcomes might not look the same.

This doesn’t necessarily mean that CAR T-cell therapy won’t eventually take the place of high-dose therapy or consolidation. Studies have been geared in this direction. Right now, CAR T cells are just a line of therapy, and it won’t have much of an effect of the role of transplant.


Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

If chimeric antigen receptor (CAR) T-cell therapy is taken out of the mix, stem cell transplant remains a critical part of the management of newly diagnosed patients, Shain says. The data continue to evolve in terms of overall survival benefit. However, progression-free survival and depth of response is where the inclusion of transplant has its greatest impact. The ideal sequence of treatment for this patient population is induction therapy, transplant, and then maintenance therapy, Shain says. Without transplant, the outcomes might not look the same.

This doesn’t necessarily mean that CAR T-cell therapy won’t eventually take the place of high-dose therapy or consolidation. Studies have been geared in this direction. Right now, CAR T cells are just a line of therapy, and it won’t have much of an effect of the role of transplant.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x